Monday, 21 November 2016

Global & Usa Cancer Immunotherapy Market Overview, Trends and Forecasts to 2020

This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials.

Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion.  Any drug that can provide a reasonable survival of more than five years for cancer patients can achieve a blockbuster status. Within cancer therapeutics, immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only cancer cells.

Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone. This report describes the evolution of such a huge market in 20 chapters supported by over 180 tables and figures in 317 pages.
  • An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.
  • Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines.
  • Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.
  • Descriptions of more than 23 cancer immunotherapeutics approved and used as targeted drugs
  • Insight into the various immunotherapeutics available for specific cancer types.
  • Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.
  • Overall global cancer therapeutics market, leading market players and the best selling cancer drugs.
  • Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs.
  • Profiles, marketed products and products in the pipeline of 79 companies that are mostly located in the U.S. and Europe.
  • Summary table to identify the category of immunotherapy drug offered by the 79 companies.
The report is supported by over 180 tables & figures over 317 pages. This report is presented as follows:
  • The global market for cancer immunotherapy by the following sub-categories are presented:
  • By Segment (Monoclonal Antibodies, Cancer Vaccines, Non-Specific Therapies, Checkpoint Inhibitors)
  • By Product Segment (Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT) & IDO Inhibitors)
  • By Company (e.g Amgen, Merck, Eli Lilly, GlaxoSmithKline, Janssen, Genentech, Roche, Bristol Myers Squibb)
To get sample request:

A comprehensive account of company product portfolios are provided for 79 Cancer Immunotherapy pharma and biotech companies including:
  • Amgen Inc.
  • Biogen Idec Inc.x
  • Bristol-Myers Squibb Co.
  • Cellectis
  • Cellerant Therapeutics Inc.
  • Celldex Therapeutics
  • Eli Lilly and Co.
  • EMD Serono Inc.
  • Genentech Inc.
  • Genmab AS
  • GlaxoSmithKline
  • ImmunoGen Inc.
  • Immunomedics Inc.
  • Janssen Biotech Inc.
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.
  • Oxford BioTherapeutics Ltd.
  • Progenics Pharmaceuticals Inc.
  • Roche Holdings Inc.
  • Seattle Genetics Inc.
  • Sorrento Therapeutics Inc.
  • Kite Pharma
  • Novartis

No comments:

Post a Comment